LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study
Metrics: PDF 1108 views | HTML 1962 views | ?
Jiao Zhang1,*, Huiran Lin3,*, Jiaxiang Wang1, Jing He2, Da Zhang1, Pan Qin1, Lin Yang1 and Lizhao Yan1
1Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
2Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
3Animal Experimental Management Center, Public Technology Service Platform, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, Guangdong, China
*These authors contributed equally to this work
Jiao Zhang, email: [email protected]
Jing He, email: [email protected]
Keywords: LMO1, neuroblastoma, GWAS, polymorphism, susceptibility
Received: June 05, 2017 Accepted: July 25, 2017 Published: August 07, 2017
Previous genome-wide association and validation studies suggest that LIM domain only 1 (LMO1) gene polymorphisms affect neuroblastoma susceptibility. In this work, we used Taqman methodology to genotype four LMO1 polymorphisms (rs110419 A > G, rs4758051 G > A, rs10840002 A > G and rs204938 A > G) in 118 neuroblastoma cases and 281 controls from Northern China. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the association. We found that rs4758051 G > A was associated with a decreased neuroblastoma risk (AA vs. GG: adjusted OR = 0.28, 95% CI = 0.13–0.62; AG/AA vs. GG: adjusted OR = 0.62, 95% CI = 0.40–0.97; AA vs. GG/AG: adjusted OR = 0.33, 95% CI = 0.15–0.69). Likewise, carrying the rs10840002 G allele was also associated with a decreased neuroblastoma risk in this Northern Chinese population. In a combination analysis using Southern and Northern Chinese populations, we found that those carrying the rs110419 G, rs4758051 A or rs10840002 G allele were at decreased neuroblastoma risk, and this finding was supported by a false-positive report probability analysis. These results further verify that LMO1 polymorphisms are protective against neuroblastoma. Case-control studies with larger samples and using other ethnicities are still needed to confirm our conclusion.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.